Dyadic (DYAI) Q2 FY26 earnings call

Dyadic is actively transitioning from a technology platform developer to a commercially driven business, evidenced by initial product sales and partner-led commercialization across life sciences, food and nutrition, and bioindustrial markets. The company is also advancing its biopharmaceutical programs through external funding, validating its C1 platform's capabilities in speed and productivity. Despite these operational advancements, the company faces significant liquidity challenges, leading to a going concern disclosure, and is actively pursuing various financing alternatives, including non